Journal: The Journal of Clinical Investigation

Article Title: Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance

doi: 10.1172/JCI188989

Figure Lengend Snippet: ( A ) Schematic of the treatment with anti–PD-1 and/or anti-CCL2 in mice from the PKD1-NC and PKD1-OE groups. ( B ) Tumor growth curves of mice in the PKD1-NC and PKD1-OE groups treated with anti–PD-1 and/or anti-CCL2 antibodies. P values were calculated via 2-tailed unpaired Student’s t tests. ( C ) Multiplex immunofluorescence results of CD45 + CD8 + cells. Left: Representative multiplex immunofluorescence images. Right: Quantitative analysis across treatment groups. Statistical comparisons were performed using Dunnett’s test, with the vehicle group designated as the reference control. ( D ) Multiplex immunofluorescence results of F4/80 + CD86 + cells. Left: Representative multiplex immunofluorescence images. Right: Quantitative analysis across treatment groups. P values were assessed using Dunnett’s test. ( E ) Heatmap showing immune cell infiltration in the tumor immune microenvironment across treatment groups (vehicle, anti–PD-1, anti-CCL2, and combined), based on bulk RNA-seq of murine TNBC. P values were calculated using the Kruskal-Wallis test. CCL2, C-C motif chemokine ligand 2; TNBC, triple-negative breast cancer; NC, negative control; OE, overexpression. * P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: Mice assigned to immunotherapy were given 5 intraperitoneal injections of 200 μg InVivoMAb anti-mouse PD-1 (Bio X Cell) or/and anti-mouse CCL2-InVivo (Selleck) every third day.

Techniques: Multiplex Assay, Immunofluorescence, Control, RNA Sequencing, Negative Control, Over Expression